<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02790034</url>
  </required_header>
  <id_info>
    <org_study_id>Sarizotan/001/II/2015</org_study_id>
    <nct_id>NCT02790034</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms</brief_title>
  <official_title>A Randomised, Double-Blind, Placebo-Controlled 6-month Study to Evaluate the Efficacy, Safety, and Tolerability of Sarizotan in Patients With Rett Syndrome With Respiratory Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Newron Pharmaceuticals SPA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Newron Pharmaceuticals SPA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety, tolerability and efficacy of Sarizotan in reducing
      respiratory abnormalities in Rett Syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled study designed to evaluate the safety,
      tolerability, and efficacy of multiple doses of sarizotan in patients with Rett syndrome with
      respiratory abnormalities. The study participants will be randomized to either sarizotan
      between 2 and 10 mg bid or placebo bid, based on age and weight criteria.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in respiratory abnormality in patients with Rett syndrome</measure>
    <time_frame>3 days prior to Baseline up to week 24</time_frame>
    <description>Measured as the percent reduction in the number of apnea episodes per hour during awake time, calculated using an ambulatory data acquisition system (BioRadioTM) as part of home monitoring procedure. BioRadioTM record specific respiratory and cardiac parameters.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of sarizotan assessed by the caregiver</measure>
    <time_frame>24 weeks</time_frame>
    <description>Caregiver-rated Impression of Change (CIC): 7-point scale requiring the caregiver to rate how much the patient's illness has improved or worsened relative to the baseline state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of sarizotan in patients with Rett syndrome with respiratory symptoms.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Adverse events (AEs),Vital signs (systolic/diastolic blood pressure, pulse, body weight, body temperature, respiratory rate),Laboratory evaluations (blood chemistry, hematology, urinalysis, plasma ACTH, cortisol and prolactin),Electrocardiogram (ECG) - 12-lead standard,Physical examination Neurological examination, Ophthalmology examination (including OCT if feasible), Tanner staging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory symptoms - Percent time spent with breathing dysrhythmia per hour</measure>
    <time_frame>24 weeks</time_frame>
    <description>Percent time spent with breathing dysrhythmia per hour. These respiratory outcomes will be determined by assessment of changes in intra-subject values and group mean change values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory symptoms - Number of hyperventilation episodes</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of hyperventilation episodes. These respiratory outcomes will be determined by assessment of changes in intra-subject values and group mean change values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory symptoms - Oxygen saturation</measure>
    <time_frame>24 weeks</time_frame>
    <description>Oxygen saturation. These respiratory outcomes will be determined by assessment of changes in intra-subject values and group mean change values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory symptoms - Respiratory Distress Index;</measure>
    <time_frame>24 weeks</time_frame>
    <description>Respiratory Distress Index; These respiratory outcomes will be determined by assessment of changes in intra-subject values and group mean change values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory symptoms - Incidence of breathing dysrhythmia episodes</measure>
    <time_frame>24 weeks</time_frame>
    <description>Incidence of breathing dysrhythmia episodes. These respiratory outcomes will be determined by assessment of changes in intra-subject values and group mean change values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor behaviour</measure>
    <time_frame>24 weeks</time_frame>
    <description>Assessed by Motor-Behavioral Assessment Scale:
I. Behavioral/Social Assessment - 16 items II. Orofacial/Respiratory Assessment - 7 items III. Motor Assessment/Physical Signs - 14 items.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global change from baseline</measure>
    <time_frame>24 weeks</time_frame>
    <description>assessed by the Clinical Global Impression of Change (CGI-C): 7-point scale requiring the clinician to rate how much the patient's illness has improved or worsened relative to the baseline state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver burden</measure>
    <time_frame>24 weeks</time_frame>
    <description>Caregiver Top 3 Concerns: Visual Analogue Scale-based evaluation of three priority concerns identified by caregivers related to the patient's RTT syndrome which they would like to see change as a result of treatment. The severity of these concerns is rated by the caregiver at baseline and is evaluated again at subsequent follow-up visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall assessment of symptoms of Rett syndrome</measure>
    <time_frame>24 weeks</time_frame>
    <description>Assessed by Rett Syndrome Clinical Severity Scale (RCSS): Frequency and manageability of seizures, respiratory irregularities, scoliosis, ability to walk (gait apraxia), hand use, speech and sleep; yielding total and feature-specific scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics profile of sarizotan and its comparison with the profile in adults</measure>
    <time_frame>Baseline, 1 and 4 hr post-dose on Day 1, and 1 and 4 hr post-dose on Day 15</time_frame>
    <description>measurement of plasma levels of Sarizotan and its major metabolites from blood samples collected from the patients at the specified time points.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">129</enrollment>
  <condition>Rett Syndrome</condition>
  <arm_group>
    <arm_group_label>Sarizotan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Between 2 to 10 mg bid based on age and weight criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo bid respectively</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sarizotan</intervention_name>
    <description>2 to 10 mg per day of Sarizotan followed by assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients.</description>
    <arm_group_label>Sarizotan</arm_group_label>
    <other_name>sarizotan hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo BID followed by assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo capsules with microcrystalline cellulose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight ≥ 10 kg

          -  Age ≥ 4 years

          -  Diagnosis of Rett syndrome based on consensus clinical criteria and patients with
             MECP2 duplications will not be eligible.

          -  Has at least 10 episodes of breathing dysrhythmia, defined by episodes ≥10 seconds of
             breath holding (apnea), per hour during cardiorespiratory monitoring

          -  Ability to take study medication provided either as capsules or combined with
             food/drink.

          -  Patient is cooperative, willing to complete all aspects of the study, and capable of
             doing so with assistance of a caregiver.

        Exclusion Criteria:

          -  Meets any of the diagnostic exclusion criteria for Rett syndrome, Typical (Neul et al,
             2010);

          -  Patient is participating in a clinical trial with another investigational drug

          -  Hypersensitivity to sarizotan or other 5-HT1a agonists;

          -  Current clinically significant (as determined by Investigator) cardiovascular,
             respiratory (e.g. severe asthma), gastrointestinal, renal, hepatic, hematologic or
             other medical disorders, in addition to those directly related to the patient's Rett
             syndrome;

          -  QTcF interval on the ECG is greater than 450 msec.

          -  Surgery planned during the study (except for insertion of gastrostomy tube);

          -  Severe diabetes mellitus or fatty acid oxidation disorder.

          -  Ophthalmologic history including any of the following conditions: albino patients,
             family history of hereditary retinal disease, retinitis pigmentosa, any active
             retinopathy or severe diabetic retinopathy.

          -  Females who are pregnant, breastfeeding, or of childbearing potential and not using a
             hormonal contraceptive.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ravi Anand, MD</last_name>
    <role>Study Director</role>
    <affiliation>Newron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ravi Anand, MD</last_name>
    <phone>+39 026103461</phone>
    <email>ravi@anand.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Lane</last_name>
      <phone>205-934-1130</phone>
      <email>jlane@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Alan Percy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Ditslear</last_name>
      <phone>858-246-2288</phone>
      <email>kditslear@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Haas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Rhode</last_name>
      <phone>312-942-0079</phone>
      <email>susan_rohde@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Heydemann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gillette Children's Specialty Healthcare</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Katoch</last_name>
      <phone>651-325-2331</phone>
      <email>RKatoch@gillettechildrens.com</email>
    </contact>
    <investigator>
      <last_name>Arthur Beisang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad Naqvi</last_name>
      <phone>832-824-3634</phone>
      <email>mfnaqvi@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>Daniel Glaze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Metropolitan Health Service Fiona Stanley Hospital</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6961</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Downs, PhD</last_name>
      <phone>.+61 8 9489 7774</phone>
      <email>Jenny.Downs@telethonkids.org.au</email>
    </contact>
    <investigator>
      <last_name>Janine Spencer, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amrita Institute of Medical Sciences</name>
      <address>
        <city>Kochi</city>
        <state>Kerala</state>
        <zip>682041</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vinayan KP, MD</last_name>
      <phone>+91 9447800303</phone>
      <email>vinayankp@aims.amrita.edu</email>
    </contact>
    <investigator>
      <last_name>Vinayan KP, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vijaya Health Centre</name>
      <address>
        <city>Chennai</city>
        <state>Tamilnadu</state>
        <zip>600 026</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandhiya Thangaraj</last_name>
      <phone>+91 7871881270</phone>
      <email>sandhiyadevi12345@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Suresh Kumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Apollo Gleneagles Hospitals</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700054</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arijit Chattopadhyay, MD</last_name>
      <phone>+919830133133</phone>
      <email>arijitchatto@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Arijit Chattopadhyay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>P.D. Hinduja National Hospital and Medical Research Centre</name>
      <address>
        <city>Mumbai</city>
        <zip>400 016</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vrajesh Udani, MD</last_name>
      <phone>+9819596661</phone>
      <email>vrajesh.udani@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Vrajesh Udani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jaslok Hospital and Research centre</name>
      <address>
        <city>Mumbai</city>
        <zip>400 026</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anaita Hegde, MD</last_name>
      <phone>+91 982 018 6155</phone>
      <email>docanaita@rediffmail.com</email>
    </contact>
    <investigator>
      <last_name>Anaita Hedge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>All India Institute of Medical Sciences</name>
      <address>
        <city>New Delhi</city>
        <zip>110 029</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheffali Gulati</last_name>
      <phone>+91 986 839 7532</phone>
      <email>sheffaligulati@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sheffali Gulati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. Senese Policlinico Santa Maria alle Scotte</name>
      <address>
        <city>Siena</city>
        <state>Tuscany</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Leoncini</last_name>
      <phone>+390577586534</phone>
      <email>s.leoncini74@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jousef Hayek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Neuropsichiatria Infantile</name>
      <address>
        <city>Milano</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miriam Nella Savini</last_name>
      <phone>390281844201</phone>
      <email>miriam.savini@yahoo.it</email>
    </contact>
    <investigator>
      <last_name>Aglaia Vignoli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 8AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asimina Tsirka</last_name>
      <phone>440207 848 0690</phone>
      <email>asimina.tsirka@kcl.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Efisia Saia</last_name>
      <phone>4402078480358</phone>
      <email>Efisia.Sais@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Santosh Paramala, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>India</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Abdala AP, Dutschmann M, Bissonnette JM, Paton JF. Correction of respiratory disorders in a mouse model of Rett syndrome. Proc Natl Acad Sci U S A. 2010 Oct 19;107(42):18208-13. doi: 10.1073/pnas.1012104107. Epub 2010 Oct 4.</citation>
    <PMID>20921395</PMID>
  </reference>
  <reference>
    <citation>Abdala AP, Bissonnette JM, Newman-Tancredi A. Pinpointing brainstem mechanisms responsible for autonomic dysfunction in Rett syndrome: therapeutic perspectives for 5-HT1A agonists. Front Physiol. 2014 May 30;5:205. doi: 10.3389/fphys.2014.00205. eCollection 2014.</citation>
    <PMID>24910619</PMID>
  </reference>
  <reference>
    <citation>Abdala AP, Lioy DT, Garg SK, Knopp SJ, Paton JF, Bissonnette JM. Effect of Sarizotan, a 5-HT1a and D2-like receptor agonist, on respiration in three mouse models of Rett syndrome. Am J Respir Cell Mol Biol. 2014 Jun;50(6):1031-9. doi: 10.1165/rcmb.2013-0372OC.</citation>
    <PMID>24351104</PMID>
  </reference>
  <reference>
    <citation>Adams JA, Zabaleta IA, Stroh D, Sackner MA. Measurement of breath amplitudes: comparison of three noninvasive respiratory monitors to integrated pneumotachograph. Pediatr Pulmonol. 1993 Oct;16(4):254-8.</citation>
    <PMID>8265274</PMID>
  </reference>
  <reference>
    <citation>Bloch KE, Li Y, Sackner MA, Russi EW. Breathing pattern during sleep disruptive snoring. Eur Respir J. 1997 Mar;10(3):576-86.</citation>
    <PMID>9072988</PMID>
  </reference>
  <reference>
    <citation>Brouillette RT, Morrow AS, Weese-Mayer DE, Hunt CE. Comparison of respiratory inductive plethysmography and thoracic impedance for apnea monitoring. J Pediatr. 1987 Sep;111(3):377-83.</citation>
    <PMID>3625404</PMID>
  </reference>
  <reference>
    <citation>Byard RW. Forensic issues and possible mechanisms of sudden death in Rett syndrome. J Clin Forensic Med. 2006 Feb;13(2):96-9. Epub 2005 Nov 2.</citation>
    <PMID>16263320</PMID>
  </reference>
  <reference>
    <citation>Cantineau JP, Escourrou P, Sartene R, Gaultier C, Goldman M. Accuracy of respiratory inductive plethysmography during wakefulness and sleep in patients with obstructive sleep apnea. Chest. 1992 Oct;102(4):1145-51.</citation>
    <PMID>1395758</PMID>
  </reference>
  <reference>
    <citation>Clarenbach CF, Senn O, Brack T, Kohler M, Bloch KE. Monitoring of ventilation during exercise by a portable respiratory inductive plethysmograph. Chest. 2005 Sep;128(3):1282-90.</citation>
    <PMID>16162719</PMID>
  </reference>
  <reference>
    <citation>Collop NA, Anderson WM, Boehlecke B, Claman D, Goldberg R, Gottlieb DJ, Hudgel D, Sateia M, Schwab R; Portable Monitoring Task Force of the American Academy of Sleep Medicine. Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive sleep apnea in adult patients. Portable Monitoring Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med. 2007 Dec 15;3(7):737-47.</citation>
    <PMID>18198809</PMID>
  </reference>
  <reference>
    <citation>Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0, May 28, 2009 (v4.03 June 14, 2010), U.S. Department of Health and Human Services.</citation>
  </reference>
  <reference>
    <citation>FitzGerald PM, Jankovic J, Percy AK. Rett syndrome and associated movement disorders. Mov Disord. 1990;5(3):195-202.</citation>
    <PMID>2388636</PMID>
  </reference>
  <reference>
    <citation>Guy W (Ed). Clinical Global Impressions. In ECDEU Assessment Manual for Psychopharmacology, revised, U.S. Department of Health, Education and Welfare Pub. No. (ADM) 76-338. Rockville, MD: NIMH, 1976, 217-222.</citation>
  </reference>
  <reference>
    <citation>Hammer J, Newth CJ, Deakers TW. Validation of the phase angle technique as an objective measure of upper airway obstruction. Pediatr Pulmonol. 1995 Mar;19(3):167-73.</citation>
    <PMID>7792119</PMID>
  </reference>
  <reference>
    <citation>Julu PO, Kerr AM, Hansen S, Apartopoulos F, Jamal GA. Immaturity of medullary cardiorespiratory neurones leading to inappropriate autonomic reactions as a likely cause of sudden death in Rett's syndrome. Arch Dis Child. 1997 Nov;77(5):464-5.</citation>
    <PMID>9487980</PMID>
  </reference>
  <reference>
    <citation>Julu PO, Kerr AM, Apartopoulos F, Al-Rawas S, Engerström IW, Engerström L, Jamal GA, Hansen S. Characterisation of breathing and associated central autonomic dysfunction in the Rett disorder. Arch Dis Child. 2001 Jul;85(1):29-37.</citation>
    <PMID>11420195</PMID>
  </reference>
  <reference>
    <citation>Julu PO, Engerström IW, Hansen S, Apartopoulos F, Engerström B, Pini G, Delamont RS, Smeets EE. Cardiorespiratory challenges in Rett's syndrome. Lancet. 2008 Jun 14;371(9629):1981-3. doi: 10.1016/S0140-6736(08)60849-1.</citation>
    <PMID>18555901</PMID>
  </reference>
  <reference>
    <citation>Katz DM, Dutschmann M, Ramirez JM, Hilaire G. Breathing disorders in Rett syndrome: progressive neurochemical dysfunction in the respiratory network after birth. Respir Physiol Neurobiol. 2009 Aug 31;168(1-2):101-8. doi: 10.1016/j.resp.2009.04.017. Epub 2009 Apr 24. Review.</citation>
    <PMID>19394452</PMID>
  </reference>
  <reference>
    <citation>Kerr AM, Armstrong DD, Prescott RJ, Doyle D, Kearney DL. Rett syndrome: analysis of deaths in the British survey. Eur Child Adolesc Psychiatry. 1997;6 Suppl 1:71-4.</citation>
    <PMID>9452925</PMID>
  </reference>
  <reference>
    <citation>Khwaja OS, Ho E, Barnes KV, O'Leary HM, Pereira LM, Finkelstein Y, Nelson CA 3rd, Vogel-Farley V, DeGregorio G, Holm IA, Khatwa U, Kapur K, Alexander ME, Finnegan DM, Cantwell NG, Walco AC, Rappaport L, Gregas M, Fichorova RN, Shannon MW, Sur M, Kaufmann WE. Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. Proc Natl Acad Sci U S A. 2014 Mar 25;111(12):4596-601. doi: 10.1073/pnas.1311141111. Epub 2014 Mar 12.</citation>
    <PMID>24623853</PMID>
  </reference>
  <reference>
    <citation>Konno K, Mead J. Measurement of the separate volume changes of rib cage and abdomen during breathing. J Appl Physiol. 1967 Mar;22(3):407-22.</citation>
    <PMID>4225383</PMID>
  </reference>
  <reference>
    <citation>Landon C. Respiratory monitoring: Advantages of inductive plethysmography over impedance pneumograpy. VivoMetrics, VMLA-039-02, 2003.</citation>
  </reference>
  <reference>
    <citation>Leino K, Nunes S, Valta P, Takala J. Validation of a new respiratory inductive plethysmograph. Acta Anaesthesiol Scand. 2001 Jan;45(1):104-11.</citation>
    <PMID>11152021</PMID>
  </reference>
  <reference>
    <citation>Loube DI, Andrada T, Howard RS. Accuracy of respiratory inductive plethysmography for the diagnosis of upper airway resistance syndrome. Chest. 1999 May;115(5):1333-7.</citation>
    <PMID>10334149</PMID>
  </reference>
  <reference>
    <citation>Neul JL, Fang P, Barrish J, Lane J, Caeg EB, Smith EO, Zoghbi H, Percy A, Glaze DG. Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome. Neurology. 2008 Apr 15;70(16):1313-21. doi: 10.1212/01.wnl.0000291011.54508.aa. Epub 2008 Mar 12.</citation>
    <PMID>18337588</PMID>
  </reference>
  <reference>
    <citation>Neul JL, Kaufmann WE, Glaze DG, Christodoulou J, Clarke AJ, Bahi-Buisson N, Leonard H, Bailey ME, Schanen NC, Zappella M, Renieri A, Huppke P, Percy AK; RettSearch Consortium. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol. 2010 Dec;68(6):944-50. doi: 10.1002/ana.22124.</citation>
    <PMID>21154482</PMID>
  </reference>
  <reference>
    <citation>Neul JL, Glaze DG, Percy AK, Feyma T, Beisang A, Dinh T, Suter B, Anagnostou E, Snape M, Horrigan J, Jones NE. Improving Treatment Trial Outcomes for Rett Syndrome: The Development of Rett-specific Anchors for the Clinical Global Impression Scale. J Child Neurol. 2015 Nov;30(13):1743-8. doi: 10.1177/0883073815579707. Epub 2015 Apr 20.</citation>
    <PMID>25895911</PMID>
  </reference>
  <reference>
    <citation>Sackner MA, Watson H, Belsito AS, Feinerman D, Suarez M, Gonzalez G, Bizousky F, Krieger B. Calibration of respiratory inductive plethysmograph during natural breathing. J Appl Physiol (1985). 1989 Jan;66(1):410-20.</citation>
    <PMID>2917945</PMID>
  </reference>
  <reference>
    <citation>Weng SM, Bailey ME, Cobb SR. Rett syndrome: from bed to bench. Pediatr Neonatol. 2011 Dec;52(6):309-16. doi: 10.1016/j.pedneo.2011.08.002. Epub 2011 Nov 6. Review.</citation>
    <PMID>22192257</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2016</study_first_submitted>
  <study_first_submitted_qc>May 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2016</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Rett Syndrome</mesh_term>
    <mesh_term>Signs and Symptoms, Respiratory</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

